» Articles » PMID: 25024312

Neuroprotective Role of Trans-resveratrol in a Murine Model of Familial Alzheimer's Disease

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2014 Jul 16
PMID 25024312
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

The amyloid-β protein precursor/presenilin 1 (AβPP/PS1) mouse model of Alzheimer's disease (AD) has provided robust neuropathological hallmarks of familial AD-like pattern. AD is a neurodegenerative process that causes severe cognitive impairment; it is characterized by the accumulation of amyloid-β (Aβ) and hyperphosphorylated tau forms and by oxidative and inflammatory processes in brain. Currently, efforts are made to understand biochemical pathways because there is no effective therapy for AD. Resveratrol is a polyphenol that induces expression and activation of several neuroprotective pathways involving Sirtuin1 and AMPK. The objective of this work was to assess the effect of oral resveratrol administration on AβPP/PS1 mice. Long-term resveratrol treatment significantly prevented memory loss as measured by the object recognition test. Moreover, resveratrol reduced the amyloid burden and increased mitochondrial complex IV protein levels in mouse brain. These protective effects of resveratrol were mainly mediated by increased activation of Sirtuin 1 and AMPK pathways in mice. However, an increase has been observed in IL1β and TNF gene expression, indicating that resveratrol promoted changes in inflammatory processes, although no changes were detected in other key actors of the oxidative stress pathway. Taken together, our findings suggest that resveratrol is able to reduce the harmful process that occurs in AβPP/PS1 mouse hippocampus, preventing memory loss.

Citing Articles

Exploring nutraceutical approaches linking metabolic syndrome and cognitive impairment.

Sonnino R, Ciccarelli G, Moffa S, Soldovieri L, Giuseppe G, Brunetti M iScience. 2025; 28(2):111848.

PMID: 40008362 PMC: 11850164. DOI: 10.1016/j.isci.2025.111848.


Insights Into the Therapeutic Potential of SIRT1-modifying Compounds for Alzheimer's Disease: A Focus on Molecular Mechanisms.

AlHayani D, Kubaev A, Uthirapathy S, Mandaliya V, Ballal S, Kalia R J Mol Neurosci. 2025; 75(1):29.

PMID: 40000535 DOI: 10.1007/s12031-025-02324-9.


Resveratrol-A Promising Therapeutic Agent with Problematic Properties.

Radeva L, Yoncheva K Pharmaceutics. 2025; 17(1).

PMID: 39861780 PMC: 11768323. DOI: 10.3390/pharmaceutics17010134.


The Promise of Epigenetic Editing for Treating Brain Disorders.

Gonzalez Molina L, Dolga A, Rots M, Sarno F Subcell Biochem. 2025; 108():111-190.

PMID: 39820862 DOI: 10.1007/978-3-031-75980-2_4.


Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.

Rojo A, Buttari B, Cadenas S, Carlos A, Cuadrado A, Falcao A Redox Biol. 2024; 79():103464.

PMID: 39709790 PMC: 11733061. DOI: 10.1016/j.redox.2024.103464.